Ofer Wellisch, MD
Pain Medicine · Stamford, CTNPI 1114189578
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (23.3%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 52.4% of the total. Reporting peaked in 2020 at $7,609 and has fallen 92.3% since, to $588 in 2025. Among pain medicine clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 83 payments — averaging $215.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$9K
- Bioness Inc$4K
- Boston Scientific$2K
- Abbott$1K
- Medtronic$299
- Saluda Medical Americas, Inc.$242
- plus $858 from 7 others
Across 2 payments — averaging $4638.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bioventus LLC$9K
What the payments were for
- Consulting fees$3,30018%
- Speaking & faculty fees$4,16023%
- Travel & lodging$3,56420%
- Food & beverage$3,27018%
- Education$2,37413%
- Entertainment$1,1957%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $9,368 |
| Bioness Inc | 4 | $3,545 |
| Boston Scientific | 21 | $2,191 |
| Abbott | 17 | $1,360 |
| Medtronic(2 entities) | 2 | $299 |
| Saluda Medical Americas, Inc. | 3 | $242 |
| Biotronik NRO, Inc. | 6 | $233 |
| Nevro Corp. | 3 | $192 |
| SPR Therapeutics, Inc | 5 | $134 |
| Flowonix Medical Incorporated | 1 | $110 |
| Amgen | 1 | $109 |
| Curonix LLC | 1 | $56 |
| Impel Pharmaceuticals Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RELISTOR$5,901
- Stimrouter for pain$3,545
- LUCEMYRA$3,137
- Superion Indirect Decompression System$959
- Proclaim Family of SCS IPGs$915
- SPECTRA WAVEWRITER$271
- GENERAL PAIN MANAGEMENT$232
- VANTA ADAPTIVESTIM$200
- Senza$174
- WaveWriter Alpha Prime 16$171
- Evoke SCS$151
- Prometra II$110
- AIMOVIG$109
How this compares
$17,863 in reported general payments places this provider in the 95th percentile of 69 pain medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MovantikNaloxegol Oxalate | 100 | $59,422 |
| BelbucaBuprenorphine Hcl | 65 | $46,435 |
| Nurtec OdtRimegepant Sulfate | 22 | $40,651 |
| Aimovig AutoinjectorErenumab-Aooe | 37 | $34,575 |
| RelistorMethylnaltrexone Bromide | 11 | $25,470 |
| HorizantGabapentin Enacarbil | 13 | $21,185 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 115 | $18,256 |
| Duloxetine Hcl | 511 | $11,816 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 16 | $10,121 |
| LinzessLinaclotide | 17 | $9,467 |
| Pregabalin | 212 | $9,467 |
| Gabapentin | 440 | $8,501 |
| Celecoxib | 301 | $6,240 |
| Oxycodone Hcl | 328 | $5,430 |
| Tramadol Hcl | 208 | $2,777 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $9,368 | $25,47011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 69 pain medicine providers in Connecticut.
Other pain medicine in Stamford
- Yuting XiongStamford$6K
- Andrew IlligStamford$2K
- Si ZhangStamford$1K
- Joseph HungStamford$141
- Sandeep JoharWaterbury$329K
- David GutierrezNew Haven$151K
- Brian GrosbergWest Hartford$99K
- Yili HuangNew Haven$18K
- Jared RosenbergGreenwich$12K
- Sandhya MehlaWest Hartford$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.